Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive Breast Cancer with Brain Metastases
NCT05018702Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in HER2-positive breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
anvatabart opadotin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05018702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018702.